Last reviewed · How we verify
Acalabrutinib Treatment A
Acalabrutinib Treatment A is a BTK inhibitor Small molecule drug developed by AstraZeneca. It is currently in Phase 1 development for Chronic lymphocytic leukemia, Mantle cell lymphoma. Also known as: AT.
BTK inhibitor
BTK inhibitor Used for Chronic lymphocytic leukemia, Mantle cell lymphoma.
At a glance
| Generic name | Acalabrutinib Treatment A |
|---|---|
| Also known as | AT |
| Sponsor | AstraZeneca |
| Drug class | BTK inhibitor |
| Target | BTK |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 1 |
Mechanism of action
Acalabrutinib is a potent and selective inhibitor of Bruton's tyrosine kinase (BTK), a key component in the B-cell receptor signaling complex.
Approved indications
- Chronic lymphocytic leukemia
- Mantle cell lymphoma
Common side effects
- Headache
- Diarrhea
- Nausea
Key clinical trials
- Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL) (PHASE3)
- Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (PHASE2)
- A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy (PHASE2)
- AQUALIS:QoL of CLL Patients Treated With Acalabrutinib in France, Retrospective Study Based on Data From PLATON Database
- A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma (PHASE2)
- Hypertension and Arrhythmias in CLL Patients Treated With BTK Inhibitors
- Observational Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukaemia in the United Kingdom
- National Acalabrutinib Observational Study
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Acalabrutinib Treatment A CI brief — competitive landscape report
- Acalabrutinib Treatment A updates RSS · CI watch RSS
- AstraZeneca portfolio CI
Frequently asked questions about Acalabrutinib Treatment A
What is Acalabrutinib Treatment A?
How does Acalabrutinib Treatment A work?
What is Acalabrutinib Treatment A used for?
Who makes Acalabrutinib Treatment A?
Is Acalabrutinib Treatment A also known as anything else?
What drug class is Acalabrutinib Treatment A in?
What development phase is Acalabrutinib Treatment A in?
What are the side effects of Acalabrutinib Treatment A?
What does Acalabrutinib Treatment A target?
Related
- Drug class: All BTK inhibitor drugs
- Target: All drugs targeting BTK
- Manufacturer: AstraZeneca — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Chronic lymphocytic leukemia
- Indication: Drugs for Mantle cell lymphoma
- Also known as: AT
- Compare: Acalabrutinib Treatment A vs similar drugs
- Pricing: Acalabrutinib Treatment A cost, discount & access